Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alpine Immune Sciences Inc (NQ: ALPN )

10.81 +0.29 (+2.71%)
Streaming Delayed Price Updated: 1:50 PM EDT, Jun 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 57,730
Open 10.39
Bid (Size) 10.82 (1)
Ask (Size) 10.90 (4)
Prev. Close 10.53
Today's Range 10.39 - 10.98
52wk Range 4.820 - 10.95
Shares Outstanding 23,914,879
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific Congresses
From Alpine Immune Sciences, Inc.
Via Business Wire
Recap: Alpine Immune Sciences Q1 Earnings
 
Via Benzinga

Performance

YTD
+45.56%
+45.56%
1 Month
+46.35%
+46.35%
3 Month
+35.87%
+35.87%
6 Month
+60.46%
+60.46%
1 Year
+20.17%
+20.17%

More News

Read More
Alpine Immune Sciences Reports First Quarter 2023 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Announces Participation in the Bank of America Securities Healthcare Conference
From Alpine Immune Sciences, Inc.
Via Business Wire
Earnings Preview: Alpine Immune Sciences
Via Benzinga
Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Earnings Scheduled For March 23, 2023
Via Benzinga
Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data and Clinical Pharmacokinetic & Pharmacodynamic Modeling at Upcoming Scientific Conferences
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data at the 2023 American Academy of Dermatology Annual Meeting
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences to Report Fourth Quarter and Full Year 2022 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences to Participate in the SVB Securities Global Biopharma Conference
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Announces Participation in Fireside Chat at the 5th Annual Evercore ISI HealthCONx Conference
From Alpine Immune Sciences, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2023
Via Benzinga
Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2022 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences to Report Third Quarter 2022 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Presents Update Of ALPN-303 Phase 1 (RUBY-1) Clinical Data at the American Society of Nephrology Kidney Week 2022 Meeting
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at 2022 American Society of Hematology Annual Meeting & Exposition
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at Upcoming Scientific Conferences
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Stops Davoceticept Trials In Cancer Indications After Second Patient Death
Via Benzinga
Alpine Immune Sciences Terminates Enrollment of Davoceticept Clinical Studies (NEON-1 and NEON-2)
From Alpine Immune Sciences, Inc.
Via Business Wire
US Stock Futures Edge Higher; All Eyes On Fed Decision
Via Benzinga
General Mills, Lennar And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
Alpine Immune Sciences Announces Pricing of $100 Million Public Offering
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Announces Proposed Public Offering
From Alpine Immune Sciences, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.